GeneDx shares leap 50% o n non-GAAP profitability GeneDx (NASDAQ: WGS) shares enjoyed another strong surge, leaping 50% from $56.06 to $84.02 Tuesday after the company announced encouraging third-quarter results that included the achievement of a non-GAAP profitability milestone
125 k OrderlyMeds customers that reported weight loss with us * 1M + Total pounds lost by OrderlyMeds customers * 15 lbs Average weight loss on our 3-month starter plan * *Based on OrderlyMeds customer data collected from January 1, 2024 October 31, 2025
So its a strange feeling to watch a different injection, one nobody can legally buy, become the drug everyone actually talks about
It generally appears as a pink or red spot at the injection site and dissipates within a few hours
Cold Weather Cardio Walking outdoors remains feasible year-round in most Canadian cities with proper clothing
Phase 2 trials documented average weight loss of 24.2% at the 12mg dose over 48 weeks, surpassing anything previously achieved through pharmaceutical intervention alone